Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis
- 31 January 2009
- journal article
- other
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 33 (1), 92-93
- https://doi.org/10.1016/j.ijantimicag.2008.06.014
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosisJournal of Antimicrobial Chemotherapy, 2006
- Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten casesJournal of Infection, 2006
- Linezolid for the treatment of multidrug-resistant tuberculosisJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteersJournal of Antimicrobial Chemotherapy, 2003
- In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous DrugsAntimicrobial Agents and Chemotherapy, 2003